Global R&D Pipeline
My Favorite
Hot Targets:
GPRC5D
Back
Total number of drugs
83
Phase II and later clinical stages
6%
Involving companies
110
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arlocabtagene autoleucel | Arlocabtagene autoleucel | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | GPRC5D inhibitors | Juno Therapeutics, Inc. | Juno Therapeutics, Inc. Bristol Myers Squibb Co. | Phase 3 | - | - | - | - | Orphan Drug（United States） | - | - | - | - | Arlocabtagene autoleucel | - | - | detail > | |
| Talquetamab | Talquetamab | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD3 stimulants GPRC5D inhibitors ADCC Cytotoxic T lymphocytes stimulants | Janssen Pharmaceuticals, Inc. | Janssen-Cilag Pty Ltd. Janssen Research & Development LLC Janssen-Cilag International NV Johnson & Johnson (China) Investment Ltd. Janssen Pharmaceutica NV Janssen Pharmaceutical KK Janssen Scientific Affairs LLC Janssen Biotech, Inc. Johnson & Johnson Janssen, Inc. Janssen Korea Ltd. | Approved | Approved | United States China European Union Japan Canada Australia Iceland South Korea Liechtenstein Norway | 2023-08-09 | 2025-02-08 | Accelerated Approval（United States） Breakthrough Therapy（China） Breakthrough Therapy（United States） Conditional marketing approval（European Union） Orphan Drug（European Union） Orphan Drug（South Korea） Orphan Drug（United States） PRIME（European Union） Priority Review（China） Conditional marketing approval（China） Orphan Drug（Japan） | - | - | - | - | Talquetamab | - | - | detail > | |
| IBI-3003 | IBI-3003 | Trispecific T-cell engager (TriTE) | Neoplasms Immune System Diseases Cardiovascular Diseases Hemic and Lymphatic Diseases Other Diseases | BCMA inhibitors CD3 stimulants GPRC5D inhibitors | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | IBI-3003 | - | - | detail > | |
| Forimtamig | Forimtamig | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD3 stimulants GPRC5D inhibitors | - | F. Hoffmann-La Roche Ltd. Hoffmann-La Roche, Inc. Roche Holding AG | Phase 1/2 | IND Approval | - | - | - | - | - | - | - | - | Forimtamig | - | - | detail > | |
| MBS-314 | MBS-314 | Trispecific T-cell engager (TriTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | BCMA inhibitors CD3 stimulants GPRC5D inhibitors | Beijing Mabworks Biotech Co., Ltd. | Beijing Mabworks Biotech Co., Ltd. Kyinno Biotechnology Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | Orphan Drug（United States） | - | - | - | - | MBS-314 | - | - | detail > | |
| GPRC5D CAR-T cells(Shenzhen Geno-Immune Medical Institute) | GPRC5D CAR-T cells(Shenzhen Geno-Immune Medical Institute) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | GPRC5D modulators | Shenzhen Geno-Immune Medical Institute | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | GPRC5D CAR-T cells(Shenzhen Geno-Immune Medical Institute) | - | - | detail > | |
| GPRC5D CAR-T(Shanghai YaKe Biotechnology) | GPRC5D CAR-T(Shanghai YaKe Biotechnology) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | GPRC5D modulators | Shanghai Yake Biotechnology Co., Ltd | Shanghai Yake Biotechnology Co., Ltd | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | GPRC5D CAR-T(Shanghai YaKe Biotechnology) | - | - | detail > | |
| BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) | BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | BCMA modulators GPRC5D modulators | Shenzhen University General Hospital | Shenzhen University General Hospital | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) | - | - | detail > | |
| QLS32015 | QLS32015 | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD3 stimulants GPRC5D inhibitors | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | QLS32015 | - | - | detail > | |
| BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) | BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) | CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | BCMA modulators GPRC5D modulators Immunologic cytotoxicity T lymphocyte replacements | Guangzhou Bio-gene Technology Co., Ltd. | Guangzhou Bio-gene Technology Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) | - | - | detail > |
Total 83 data
1
2
3
4
5
6
7
8
9
